Skip to main content
Premium Trial:

Request an Annual Quote

FDA Buys Toxicology Data Mining Software, Databases from LeadScope

NEW YORK, Nov. 9 — LeadScope has sold its Enterprise data mining software and ToxScope toxicity databases to the US Food and Drug Administration to help the agency perform in silico  toxicology assessments.  

Under the agreement, which is an extension of a deal struck earlier in the year, the FDA will be able to use both the public toxicity information, which is provided in the ToxScope toxicity databases, together with its own data to “identify relationships between chemical structures and toxicity,” LeadScope said in a statement.

Financial terms of the sale were not disclosed.

“The FDA expects to use LeadScope in its safety assessment of food contact materials,” an FDA spokesman added. “We expect the software to be particularly useful in resolving safety questions concerning the potential mutagenicity of food contact substances.”

Earlier this year, LeadScope, of Columbus, Ohio, had collaborated with the FDA under a material transfer agreement that provides the agency with limited access to the LeadScope technology. This agreement was with the Center for Drug Evaluation and Research and the Center for Food Safety and Applied Nutrition.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.